Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 11, 2004 Roger Nusbaum	Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool November 18, 2004 Lawrence Meyers	Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction.
The Motley Fool December 28, 2004 W.D. Crotty	Pfizer: For Value Eyes Only While clearly not for conservative investors, this pharmaceutical deserves the attention of those looking for a value play.
The Motley Fool January 19, 2005 Stephen D. Simpson	Pfizer Doesn't Give Much Fizz The company reports mediocre earnings as investors remain nervous about the drug sector.
The Motley Fool August 20, 2007 Timothy M. Otte	Do You Know Mr. Market? Sage advice for volatile markets from Benjamin Graham, the father of value investing.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
The Motley Fool October 27, 2004 Rick Aristotle Munarriz	Ace in the Hole? Does the apple fall far from the tree when the orchard is ripe for resignation? These are scary days in some areas of the insurance industry.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?
The Motley Fool October 25, 2007 Sham Gad	Be Greedy When Others Are Fearful The ideas written about in the book Security Analysis more than seventy years ago are just as timely today. Investors, heed this sound advice.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool December 29, 2004 Chuck Saletta	Three Tens for a Twenty Take advantage of opportunities to get discounted pricing on companies.
The Motley Fool November 23, 2004 W.D Crotty	5 Drugs to Worry About? The recall of Merck's Vioxx raises concern among investors that there may be other pharmaceutical companies with potential legal exposure.
The Motley Fool April 8, 2005 Charly Travers	The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care?
The Motley Fool January 19, 2006 Stephen D. Simpson	Pfizer: Less Bad Is Good Enough Pfizer's quarter wasn't strong, but it was better than expected. The company may not be able to recapture past glories, but the stock is still good idea for long-term.
The Motley Fool March 22, 2007 Chuck Saletta	Inherit Warren Buffett's Investing Legacy You can become the next super-investor by buying businesses for less than they're worth. Moody's... Wells Fargo... etc.
The Motley Fool December 17, 2004 W.D. Crotty	Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
The Motley Fool September 27, 2011 Tamara Rutter	7 Investment Mistakes to Avoid Common investing mistakes that even the experts make. Even the most successful buy-and-hold investors, such as Warren Buffet and Peter Lynch, have made their fair share of mistakes.
The Motley Fool January 17, 2008 Sham Gad	You Can Profit Despite the Panic The whole point of investing is to buy low and sell high, so investors should welcome declining markets rather than cash out.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool October 20, 2004 Rogene Calvet	Is Marsh Ringing the Value Bell? Does a troubled global insurer offer a buying opportunity?
The Motley Fool April 28, 2011 Morgan Housel	Berkshire's Sokol: Misleading, Deceiving, Breaking the Rules David Sokol gets scolded by Berkshire.
The Motley Fool December 13, 2007 Mac Greer	Fool Video: Netflix, Buffett, and 5 Stocks for Skeptics What are some stocks that can turn bears into bulls? What do pharmaceutical giant Pfizer, energy company Precision Drilling, and Chinese wireless company KhongZhong have in common? These questions and others are discussed in this video.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool August 3, 2007 Rich Duprey	The Only 3 Ideas You Need Instead of buying insanely valued stocks at a premium, we should be looking at deeply discounted stocks that the market has tossed aside.
The Motley Fool August 2, 2005 Chuck Saletta	Allstate: A Stock I'd Love to Own Thanks to a banner year and an aggressive buyback program, Allstate might look a bit cheap right now. It's priced at about 12 times trailing earnings.
The Motley Fool August 30, 2007 Sham Gad	Value Investors Only Care About Bear Markets How you perform in bear markets is what counts.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.
The Motley Fool November 26, 2007 Sham Gad	Define Your Investment Goals Investing with a simple and effective framework will help you prevent significant losses. And that should always be your primary goal.
The Motley Fool September 27, 2006 David Meier	Berkshire Hathaway Is Not for Everyone If you understand Berkshire thoroughly and believe it's a bargain today, go for it. If not, don't worry. There are plenty of great investment opportunities out there.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
The Motley Fool April 22, 2005 Richard Gibbons	Buffett's Befitting Bud Buy Three intriguing things about Berkshire's latest purchase of Anheuser-Busch.
BusinessWeek March 27, 2006 Diane Brady	Hank Greenberg At War One year after Hank Greenberg was forced out of the insurance empire he built, the wounds are still raw. Then again, his battle against AIG has only just begun.
The Motley Fool May 18, 2005 Philip Durell	Buffett's AAA Discount Is Berkshire Hathaway's credit rating at risk? Investors, take note.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
BusinessWeek January 10, 2005 Amy Barrett	Pfizer Has Plenty Of Pain To Kill Many investors and analysts argue that while the drug company should continue to plow money into new-drug development, the company needs to aggressively reduce other costs and return greater amounts of cash to shareholders through a higher dividend.
The Motley Fool December 3, 2004 Whitney Tilson	Gaining an Investment Edge Here's how to beef up your portfolio and beat the market.
The Motley Fool July 16, 2010 Anand Chokkavelu	Buy, Sell, or Hold: Berkshire Hathaway With all due respect to Mr. Buffett, let's lay out the cases for buying, selling, and holding Berkshire Hathaway.
The Motley Fool October 18, 2006 Chuck Saletta	Your Edge Over Buffett With less competition chasing a larger pool of great potential investments, you've got a far better chance of finding and buying great stocks.
The Motley Fool July 27, 2009 Selena Maranjian	Let Me Save You $1.7 Million Let me offer you some of Buffett's food for thought -- even if it comes without the million-dollar meal he auctions off for charity.
BusinessWeek April 18, 2005 Marcia Vickers	Warren And Hank Are Set For A Grilling When Buffett and Greenberg meet with Spitzer and the feds, old feuds may flare. Insurance experts are wondering if the rendezvous with regulators will turn into a showdown between the two icons.
The Motley Fool October 26, 2004 Rich Duprey	Aon Mired in Marsh World's second-largest insurance broker accused of improper business practices.
The Motley Fool December 14, 2005 Steven Mallas	Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.